Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BI 905711 |
| Trade Name | |
| Synonyms | BI-905711|BI905711 |
| Drug Descriptions |
BI 905711 is a bispecific antibody that binds to and targets TRAILR2 and CDH17, potentially resulting in antitumor activity (Ann Oncol (2022) 33 (suppl_7): S136-S196). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C173541 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + BI 905711 + Fluorouracil + Irinotecan + Leucovorin | BI 905711 Bevacizumab Fluorouracil Irinotecan Leucovorin | 0 | 1 |
| BI 905711 | BI 905711 | 0 | 1 |
| BI 905711 + Fluorouracil + Irinotecan + Leucovorin | BI 905711 Fluorouracil Irinotecan Leucovorin | 0 | 1 |